All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BND-22
Therapeutic Area: Oncology Product Name: BND-22
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,125.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 12, 2021
Details:
BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NT219
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2020
Details:
The primary objectives of the open-label Phase 1/2 trial are to evaluate safety, assess pharmacokinetics, identify the appropriate dose to be studied in the Phase 2 portion, and establish preliminary efficacy of NT219.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DSP107,Atezolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Flerie Invest AB
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 25, 2020
Details:
Proceeds will be used for advancing the Company's next generation immuno-oncology drug candidates including the clinical development of the Company's lead product, DSP107, an anti-CD47 therapy.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
